Výsledky vyhledávání - "Raleigh Malik"

Tirzepatide reduces body weight across body mass index (BMI) categories: A SURMOUNT-1 pre-specified analysis

Autor: Louis J Aronne, Ania M. Jastreboff, Carel W Le Roux, Raleigh Malik, Nadia Ahmad, Bing Liu, Mathijs Bunck, Shuyu Zhang, Adam Stefanski, Anne Lautenbach

Publikováno v: Diabetologie und Stoffwechsel.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b953d52555c0683986d7782f53aab31e
https://doi.org/10.1055/s-0043-1767938

Zobrazit plný text záznamu

743-P: Effect of Once-Weekly TZP on Glycemic Control by Baseline Age in Patient Subpopulations from the SURPASS Trials

Autor: CAROL H. WYSHAM, SANTIAGO TOFE, HELENE SAPIN, RALEIGH MALIK, LISA M. NEFF

Publikováno v: Diabetes. 71

Tirzepatide (TZP) is a dual GIP and GLP-1 receptor agonist developed for the treatment of patients with type 2 diabetes (T2D) . The SURPASS clinical trials demonstrated efficacy and safety of TZP 5, 10, and 15 mg, administered once weekly in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5e8d2c23bf89602422237ec14d51b5b3
https://doi.org/10.2337/db22-743-p

Zobrazit plný text záznamu

Higher doses of dulaglutide induce weight loss in patients with type 2 diabetes (T2D) regardless of baseline BMI: post hoc analysis of AWARD-11

Autor: Enzo Bonora, Juan Frias, Raleigh Malik, Anita Kwan, Sohini Raha, Angelyn Bethel, David A. Cox, Matthias Blüher

Publikováno v: Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::039fa540afb192914b173d6a27e9b1e9
https://doi.org/10.1055/s-0042-1746329

Zobrazit plný text záznamu

Greater adherence and persistence with dulaglutide compared to semaglutide at 6- and 12-months follow-up in U.S. real-world data

Autor: Reema Mody, Janna Manjelievskaia, Maria Yu, Elizabeth H. Marchlewicz, Raleigh Malik, Nicole M. Zimmerman, Debra E. Irwin, Thorsten Siegmund

Publikováno v: Hand in Hand zum Ziel – einfach.besser.messbar www.diabeteskongress.de.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7adba65edfd5bfc2d243328ae798e5e8
https://doi.org/10.1055/s-0042-1746330

Zobrazit plný text záznamu

356-OR: Effect of Dulaglutide on Kidney Function–Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial

Autor: Charles Atisso, Helen M. Colhoun, Hertzel C. Gerstein, Fady T. Botros, Jonathan E. Shaw, Raleigh Malik

Publikováno v: Diabetes. 69

In participants with type 2 diabetes (T2D) in the REWIND trial, dulaglutide (DU) use for median follow-up of 5.4 years was associated with reduced composite renal outcomes, defined as the first occurrence of new macroalbuminuria, sustained decline in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa8c4f6152f0080ef50a762ebb4b8ab6
https://doi.org/10.2337/db20-356-or

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání